Yinghong (mimi) WangMD, PhD, MSc
Dr. Wang has a strong academic background (M.D., Ph.D., M.Sc.) and profound clinical experience from world-renowned medical programs (Johns Hopkins, Cleveland Clinic). She holds more than 50 peer-reviewed publications and national conference presentations. Her specialized areas include Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy induced gastrointestinal toxicities.
Prior to joining The University of Texas MD Anderson Cancer Center, Dr. Wang had 8 years of experience from a tertiary IBD center at Cleveland Clinic taking care of patients with complex Crohn’s Disease, and Ulcerative Colitis with or without serious complications. In addition, Dr. Wang had 2 years of clinic experience doing FMT for recurrent C diff infection at Cleveland Clinic with a high eradication rate (>95%).
At MD Anderson, Dr. Wang has been recognized for her expertise in managing cancer immunotherapy induced GI toxicities and her initiative in setting up IBD clinic and FMT service. She is taking a leading role in management guidelines for immunotherapy induced colitis in three national oncology societies.